Stockscreener 앱 받기
4.97
10.69%
0.48
시간 외 거래:
4.73
-0.24
-4.83%
전일 마감가:
$4.49
열려 있는:
$4.56
하루 거래량:
43,567
Relative Volume:
0.03
시가총액:
$57.27M
수익:
$37.79M
순이익/손실:
$-10.38M
주가수익비율:
-6.8082
EPS:
-0.73
순현금흐름:
$-1.00M
1주 성능:
+21.22%
1개월 성능:
+8.28%
6개월 성능:
+304.07%
1년 성능:
+206.79%
1일 변동 폭
$4.56
$5.15
1주일 범위
$3.975
$5.15
52주 변동 폭
$1.04
$7.25
Cumberland Pharmaceuticals Inc Stock (CPIX) Company Profile
명칭
Cumberland Pharmaceuticals Inc
전화
615-255-0068
주소
2525 WEST END AVENUE, NASHVILLE,, TN
CPIX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CPIX
Cumberland Pharmaceuticals Inc
|
4.97 | 57.27M | 37.79M | -10.38M | -1.00M | -0.73 |
|
ZTS
Zoetis Inc
|
149.99 | 66.56B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.33 | 45.76B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.45 | 45.66B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
14.00 | 16.04B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
292.82 | 12.79B | 2.76B | 1.11B | 898.10M | 22.77 |
Cumberland Pharmaceuticals Inc Stock (CPIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2012-11-12 | 재확인 | UBS | Neutral |
| 2011-02-01 | 재확인 | UBS | Neutral |
| 2010-12-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2010-08-17 | 다운그레이드 | Jefferies | Buy → Hold |
| 2010-08-17 | 재확인 | Morgan Joseph | Buy |
| 2010-08-17 | 재확인 | UBS | Buy |
| 2010-05-14 | 재확인 | Morgan Joseph | Buy |
모두보기
Cumberland Pharmaceuticals Inc 주식(CPIX)의 최신 뉴스
Cumberland Pharmaceuticals' (NASDAQ:CPIX) growing losses don't faze investors as the stock swells 18% this past week - simplywall.st
Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Price Crosses Above 200 Day Moving Average – Here’s Why - Defense World
Cumberland Pharmaceuticals director Caroline Young acquires $383 in common stock - Investing.com Australia
Cumberland Pharmaceuticals director Kenneth Krogulski acquires $4,548 in stock By Investing.com - Investing.com South Africa
Cumberland Pharmaceuticals director James Jones buys shares worth $880 By Investing.com - Investing.com South Africa
Cumberland Pharmaceuticals director Kenneth Krogulski acquires $4,548 in stock - Investing.com
Cumberland Pharmaceuticals CEO A.J. Kazimi acquires $880 in common stock - Investing.com
Cumberland Pharmaceuticals director James Jones buys shares worth $880 - Investing.com India
Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Price Passes Above 200 Day Moving Average – What’s Next? - Defense World
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
FIGHT DMD trial results selected for late-breaking presentation at MDA clinical & scientific conference - Marketscreener.com
Breakthrough DMD Heart Disease Treatment Achieves 5.4% Function Boost While Controls Decline - Stock Titan
FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference - PR Newswire
Burn Pain Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Cumberland Pharma, Janssen R&D, Cephalon - The Globe and Mail
Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Passes Above 200-Day Moving Average – Here’s Why - Defense World
Earnings call transcript: Cumberland Q4 2024 results show revenue rise By Investing.com - Investing.com Australia
CPIX Stock Price and Chart — NASDAQ:CPIX - TradingView
Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Rating Upgraded by StockNews.com - Defense World
Cumberland Pharmaceuticals Inc. (CPIX) reports earnings - Quartz
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q4 2024 Earnings Call Transcript - MSN
Cumberland Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Cumberland Pharma stock soars to 52-week high of $7.25 By Investing.com - Investing.com Canada
Cumberland Pharmaceuticals: Key Insights from Earnings Call - TipRanks
Cumberland Pharma stock soars to 52-week high of $7.25 - Investing.com India
Cumberland Pharmaceuticals Inc (CPIX) Q4 2024 Earnings Call Highlights: Revenue Growth and ... By GuruFocus - Investing.com Canada
Cumberland: Q4 Earnings Snapshot - Midland Daily News
Cumberland Pharmaceuticals Reports Revenue Growth and Strategic Advances - TipRanks
Earnings call transcript: Cumberland Q4 2024 results show revenue rise - Investing.com
Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth - TradingView
Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth -March 04, 2025 at 04:52 pm EST - Marketscreener.com
Cumberland: Q4 Earnings Snapshot -March 04, 2025 at 04:51 pm EST - Marketscreener.com
Glenmark Pharmaceuticals Inc., USA acquires and launches Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials - BioSpace
Glenmark Pharmaceuticals Acquires & Launches Acetylcysteine Injection In The U.S. - BW Healthcare World
Glenmark acquires Acetylcysteine injection, launches in US market - BusinessLine
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Held Back By Insufficient Growth Even After Shares Climb 117% - Simply Wall St
Investor Network: Cumberland Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Cumberland Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS - PR Newswire
When Will Cumberland Pharmaceuticals Reveal Its 2024 Performance? Key Date for Specialty Pharma Investors - Stock Titan
(CPIX) Trading Report - news.stocktradersdaily.com
Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Have A Healthy Balance Sheet? - Simply Wall St
Cumberland Pharma stock soars to 52-week high of $6.43 By Investing.com - Investing.com South Africa
Cumberland Pharma stock soars to 52-week high of $6.43 - Investing.com
Cumberland Pharmaceuticals' Pneumonia Injection Receives Approval in China -February 18, 2025 at 08:19 am EST - Marketscreener.com
VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA - Finansavisen
Corneal Ulcer Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, NDA Approval, Prevalence, Incidence, Therapies, and Companies by DelveInsight - The Globe and Mail
Cumberland Pharmaceuticals Inc (CPIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.83%
1.04%
자본화:
|
볼륨(24시간):